Richard L. Lindstrom

Lindstrom’s Perspective

Lindstrom's Perspective

A wish list for a nearly ideal IOL

Ocular Surgery News U.S. Edition, May 25, 2020
Richard L. Lindstrom, MD
The first IOL was implanted by Sir Harold Ridley on Nov. 29, 1949, at St. Thomas’ Hospital in London. Amazing to me, it was a monofocal…
Lindstrom's Perspective

Years of work, effort culminate in Holland Foundation for Sight Restoration

Ocular Surgery News U.S. Edition, May 10, 2020
Richard L. Lindstrom, MD
My commentary on the Holland Foundation for Sight Restoration will be more personal than usual. At the outset, I will disclose that I am a strong…
Lindstrom's Perspective

Immediate planning needed for personal, practice financial survival

Ocular Surgery News U.S. Edition, April 25, 2020
Richard L. Lindstrom, MD
The coronavirus pandemic is a new experience for everyone in the United States today. SARS, MERS and Ebola were rapidly contained, with no impact on…
Lindstrom's Perspective

Use ABCDs to capture patients with ocular surface disease for long term

Ocular Surgery News U.S. Edition, April 10, 2020
Richard L. Lindstrom, MD
The American Society of Cataract and Refractive Surgery Cornea Clinical Committee has provided us another excellent guideline for the diagnosis and…
Lindstrom's Perspective

Professional, personal benefits abound with successful clinical research

Ocular Surgery News U.S. Edition, March 25, 2020
Richard L. Lindstrom, MD
I am often asked by other ophthalmologists: “How do I get started working with industry?” My answer is always the same: Start by serving…
Lindstrom's Perspective

Comanagement may be needed for best uveitis care

Ocular Surgery News U.S. Edition, March 10, 2020
Richard L. Lindstrom, MD
The accompanying cover story on uveitis is quite comprehensive, and I have only a few thoughts to add. The uveitis being discussed in this issue is…
Lindstrom's Perspective

Advances needed to alleviate burden of retinal disease treatment

Ocular Surgery News U.S. Edition, February 25, 2020
Richard L. Lindstrom, MD
We now have our fourth anti-VEGF drug, Beovu from Novartis. Each of the available drugs — Avastin, Lucentis, Eylea and Beovu — typically…
Lindstrom's Perspective

Currently, glaucoma better managed with surgery

Ocular Surgery News U.S. Edition, February 10, 2020
Richard L. Lindstrom, MD
The first minimally invasive or microinvasive glaucoma surgery to consider when treating a patient with open-angle glaucoma is selective laser…
Lindstrom's Perspective

Close monitoring needed to avoid drug-induced ocular side effects

Ocular Surgery News U.S. Edition, January 25, 2020
Richard L. Lindstrom, MD
Drug-induced ocular side effects are common in every ophthalmologist’s practice. When we review our senior patients’ lists of medicines…
Lindstrom's Perspective

Challenges of worldwide vision loss great, but potential benefits of treatment greater

Ocular Surgery News U.S. Edition, January 10, 2020
Richard L. Lindstrom, MD
The recently published WHO World Report on Vision is required reading for anyone interested in reducing the burden of vision impairment in the world…